Human plasminogen, plasma, or serum increased the pathogenicity of six streptokinase-positive streptococcal strains for mice. Combinations of commercial streptokinase and plasminogen or streptokinase and plasma did not usually increase mouse mortality to a greater degree than did plasminogen or plasma alone, suggesting that the maximal effective amount of streptokinase was produced by the organ...

background and objectives : streptokinase is used clinically as an intravenous thrombolytic agent for the treatment of acute myocardial infarction and is commonly prepared from cultures of streptococcus equisimilis strain h46a. the objective of the present study was the production of streptokinase from strain h46a and purification by chemical reduction method. materials and methods: the rate of...

determination of streptokinase activity is usually accomplished through two assay methods: a) clot lysis, b) chromogenic substrate assay. in this study the biological activity of two streptokinase products, namely streptase®, which is a native product and heberkinasa®, which is a recombinant product, was determined against the third international reference standard using the two forementioned a...

Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers a...

A series of new, covalent polyethylene glycol (PEG)-streptokinase adducts were synthesized and characterized. PEGs with average molecular weights of 2,000, 4,000, and 5,000 were activated with carbonyldiimidazole and coupled to the protein under standardized reaction conditions. Steady-state kinetic analysis demonstrated comparable Km values for the activation of plasminogen by streptokinase, P...

OBJECTIVE To evaluate the influence of pretreatment streptokinase resistance titre and the concentration of IgG antibodies to streptokinase on the efficacy of thrombolytic drugs containing streptokinase in restoring coronary patency in acute myocardial infarction. DESIGN Comparative observational study. SETTING City general hospital. PATIENTS One hundred and twenty four previously unexpos...

background: myocardial infarction (mi) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following mi in most countries including iran. our previous study showed that, the prevalence of high antibody titers a...

BACKGROUND Streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solubilize the fibrin network in blood clots. Streptokinase is currently used in clinical medicine as a thrombolytic agent. It is naturally secreted by β-hemolytic streptococci. METHODS To reach an efficient method of purification, an immunoaffinity chromatography method was developed that could puri...

OBJECTIVE To follow the change in streptokinase neutralisation titres in a group of patients after treatment with streptokinase for acute myocardial infarction. DESIGN Venous blood samples suitable for analysis were obtained up to 866 days after treatment with 1.5 million units of streptokinase in 189 patients. The ability of the patient's plasma to inhibit lysis of a thrombin clot by strepto...

A comparison was made of the esterase and activator activities of the various activated forms of human plasminogen and their streptokinase complexes with Nalpha-Cbz-L-lysine-p-nitrophenyl ester as the substrate. The steady state kinetic properties of Glu- and Lys-plasmins, and Glu- and Lys-plasminogen-streptokinase complexes were identical, while the Lys-plasmin-streptokinase complex showed a 2...